Salmeterol/Flutikason Devatis 25 mikrogram/250 mikrogram/dos Inhalationsspray, suspension

Страна: Швеція

мова: шведська

Джерело: Läkemedelsverket (Medical Products Agency)

Активний інгредієнт:

flutikasonpropionat; salmeterolxinafoat

Доступна з:

Devatis GmbH

Код атс:

R03AK06

ІПН (Міжнародна Ім'я):

fluticasone propionate; salmeterol

Дозування:

25 mikrogram/250 mikrogram/dos

Фармацевтична форма:

Inhalationsspray, suspension

Склад:

flutikasonpropionat 250 mikrog Aktiv substans; salmeterolxinafoat 36,3 mg Aktiv substans

Тип рецепту:

Receptbelagt

Огляд продуктів:

Förpacknings: Spraybehållare, 120 doser; Spraybehållare, 10 x 120 doser (sjukhusförpackning); Spraybehållare, 3 x 120 doser; Spraybehållare, 2 x 120 doser

Статус Авторизація:

Godkänd

Дата Авторизація:

2019-01-25

Характеристики продукта

1
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Salmeterol/Flutikason Devatis 25 microgram/250 microgram/actuation,
pressurised inhalation,
suspension
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each metered dose (ex valve) contains:
36.3 microgram salmeterol xinafoate equivalent to 25 micrograms of
salmeterol and 250 micrograms
of fluticasone propionate. This is equivalent to a delivered dose (ex
actuator) of 21 micrograms of
salmeterol and 220 micrograms of fluticasone propionate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Pressurised inhalation, suspension (pressurised inhalation).
White to off-white suspension in a metal container.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
{invented name} is indicated in the regular treatment of asthma where
use of a combination product
(long-acting β
2
-agonist and inhaled corticosteroid) is appropriate:

patients not adequately controlled with inhaled corticosteroids and
'as needed' inhaled short-
acting β
2
-agonist
or

patients already adequately controlled on both inhaled corticosteroid
and long-acting β
2
-agonist
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Route of administration: Inhalation use.
Patients should be made aware that {invented name} must be used daily
for optimum benefit, even
when asymptomatic.
Patients should be regularly reassessed by a doctor, so that the
strength of {invented name} they are
receiving remains optimal and is only changed on medical advice.
THE DOSE SHOULD BE TITRATED TO THE
LOWEST DOSE AT WHICH EFFECTIVE CONTROL OF SYMPTOMS IS MAINTAINED.
WHERE THE CONTROL OF
SYMPTOMS IS MAINTAINED WITH {INVENTED NAME} 25/250 MICROGRAM/ACTUATION
GIVEN TWICE DAILY
THEN THE NEXT STEP COULD INCLUDE A SWAP TO A DIFFERENT INHALED
SALMETEROL FLUTICASONE PRODUCT
AVAILABLE IN LOWER STRENGTH (25/125 MICROGRAM OR 25/50 MICROGRAM).
As an alternative, patients requiring a long-acting β
2
-agonist could be titrated to {invented name}
given once daily if, in the opinion of the prescriber,